Clinical trial · Observational
MYeloma Resistance And Clonal Evolution
NCT03807128CI-TRIAL-00092099MYRACLErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection through questionnaires | Other | — | UNRESOLVED |
| Prélèvement sanguin (2*4mL) ou médullaire (2mL) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- MYRACLE patients
- interventionNames
- Other: Prélèvement sanguin (2*4mL) ou médullaire (2mL)
- Other: Data collection through questionnaires
Primary outcomes (1)
- measure
- Describe the mechanisms of resistance of myeloma cells.
- timeFrame
- 15 years
- description
- Number of resistance.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014) * Patient having consented to participate in the study and his/her biocollection * Patient affiliated to or benefiting from a social security scheme or similar Exclusion Criteria: * Minors * Major under guardianship or curatorship * Protected persons. * Pregnant or breast-feeding women * Persons benefiting from the AME
References
Publications (2)
- DERIVEDGrandclement C, Estoppey C, Dheilly E, Panagopoulou M, Monney T, Dreyfus C, Loyau J, Labanca V, Drake A, De Angelis S, Rubod A, Frei J, Caro LN, Blein S, Martini E, Chimen M, Matthes T, Kaya Z, Edwards CM, Edwards JR, Menoret E, Kervoelen C, Pellat-Deceunynck C, Moreau P, Mbow ML, Srivastava A, Dyson MR, Zhukovsky EA, Perro M, Sammicheli S. Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma. Nat Commun. 2024 Mar 6;15(1):2054. doi: 10.1038/s41467-024-46310-y. PMID 38448430
- DERIVEDDerrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouze E. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023 Nov;4(11):1536-1543. doi: 10.1038/s43018-023-00625-9. Epub 2023 Aug 31. PMID 37653140